key: cord-0779744-oc2n1s1u
authors: Damluji, Abdulla A; Rajan, Devin; Haymond, Amanda; deFilippi, Christopher
title: Serological Testing for COVID-19 Disease: Moving the Field of Serologic Surveillance Forward
date: 2021-03-10
journal: J Appl Lab Med
DOI: 10.1093/jalm/jfab018
sha: 3f8179d8e36f5ffdbaf61b7f822dd27f2e3ccc17
doc_id: 779744
cord_uid: oc2n1s1u

nan

Since the outbreak of COVID-19, there has been a worldwide initiative to develop methods for detecting SARS-CoV-2 in the community. Numerous strategies were developed, but most lack comparative accuracy, which is critical in assessing their utility in clinical practice.

Testing strategies for COVID-19 disease can either be molecular or serological. Molecular testing is the preferred diagnostic method for symptomatic patients because it detects the presence of viral particles in the respiratory tract by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) or other methodologies. 1 Serological methods, on the other hand, is less useful for testing recent symptomatic infection because serology relies on the body's immune system to generate antibodies against foreign viral particles, a process that can take up to 3 weeks following the initial infection.

The clinical application of serologic testing include: (1) identify the individual's previous SARS-CoV-2 exposure; (2) quantify the levels and class of antibodies against SARS-CoV-2; (3) assess the ability of these antibodies to prevent reinfection (i.e. quantify the physiologic response of the antibodies to neutralize the virus's ability to infect host cells). Quantifying the neutralization response of a patient's antibodies requires a specialized laboratory and it is time consuming and expensive. Therefore, it is desirous to understand the correlation of inexpensive, high-throughput readily accessible serological binding assay quantitative testing used in clinical practice to physiologic neutralization capability. If correlated, serology testing can enhance our ability to investigate the potential of convalescent plasma donors to treat acutely ill COVID-19 patients and understand the relative immunity post-exposure in populations at greatest risk of complications (e.g. older adults, healthcare professionals, or patients with multimorbidity) if ever re-infected.

Damluji--4

Currently, as of this writing there are more than 50 serological binding assays that have FDA emergency use access. 2, 3 While the EUA for these methods is justified during the pandemic period, the lack of rigorous evaluation for these tests prior to FDA approval results in highly variable results specific to their antibody class detection, antigen targets, and format. 4 Furthermore, while there is much debate about the sensitivity and specificity of these assays, a perhaps more compelling question is to understand the association of qualitative or quantitative results with the physiologic response of the antibodies to neutralize the SARS-CoV-2 virus.

In this issue, Rychert et al. evaluated the performance of three widely utilized quantitative serological binding assays for SARS-CoV-2 IgG (Abbott SARS-CoV-2 IgG, DiaSorin Liaison SARS-CoV-2 S1/S2 IgG, and anti-SARS-CoV-2 IgG ELISA from EUROIMMUN) and whether these assays associated with neutralizing antibody response. A total of 35 samples from confirmed COVID-19 positive by RT-PCR were compared with 100 samples from 80 adult and 20 pediatric healthy doners. All specimens in each panel were tested using the three IgG immunoassays. While serologic tests vary in their antibody class detected, IgG antibodies may have a larger role than IgA and IgM because they persist longer and are thought to have a higher neutralizing activity to SARS-CoV-2, which is essential for recovery from COVID-19. 2 Seroprevalence studies indicate that over 90% of adults age 50 and older hold antibodies to all four common circulating coronaviruses, therefore, a serologic assay must target antibodies highly specific to a SARS-CoV-2 antigen. 2 Analysis of the amino acid sequences of the nucleocapsid protein (NP) and spike protein (S1) of SARS-CoV-2 (the two most common antibody targets in commercially available serologic tests) reveals less than 30% similarity to the respective homologs in other coronaviruses 2 , showing promise for high specificity. In their work, all three serologic assays showed high sensitivity, only differing in samples collected less than 5

Damluji--5 days after confirmed infection by RT-PCR molecular testing. The two chemiluminescent assays showed high specificity, even when testing serum samples from individuals who tested positive for respiratory illnesses other than COVID-19. Due to a low prevalence in some areas, it is possible that even a test with high specificity will generate high rates of false positive results in large scale serosurveys. Assuming a prevalence of 5% and a specificity of 99%, the positive predictive values (PPV) for Abbott and DiaSorin are only ~80-85%. 5 Therefore, in order to improve positive predictive value in low prevalence settings, the CDC recommends an orthogonal testing algorithm such that that positive samples are tested by another assay with a different target antigen or format. 6 A range of testing formats exist, although the most widely used and accepted binding assay tests are ELISA-or chemiluminescent-based. They identify both binding and neutralizing IgG antibodies; however, it is generally accepted that neutralizing antibodies are particularly critical for any protective immunity. 7 Neutralization assays exist, but compared to other serologic assays, require significantly more time, money, and laboratory expertise. Nonetheless, neutralization assays provide the most accurate reflection of a protective immune response by identifying the antibody concentration needed to prevent viral replication within cells in vitro.

Without rigorous FDA oversight, independent evaluation of the different serologic assays is critical in guiding utility.

When compared to the Vyriad neutralizing antibody assay used by Rychert et al, a positive IgG detection on by any of the three serologic binding assays predicted the presence of neutralizing antibodies, and therefore, show promise in their ability to discern neutralizing antibody-positive from neutralizing antibody-negative samples. However, the concentration of neutralizing antibodies detected by the Vyriad assay did not correlate well with the level of IgG Damluji--6 measured by any the three serologic assays irrespective of the target epitope. This means that the strength of the read-out (whether color, fluorescence, or radiance) of these three serologic tests (based on levels of binding and neutralizing antibodies) should not be used to evaluate the strength of the neutralizing antibody response.

In contrast to this report on three specific, FDA EUA-approved serologic tests, there have been reports of correlation between titers in other anti-spike serological assays and titers in some viral neutralization assays. 8, 9 10, 11 While it is clear that differences in the specific serologic tests utilized in a study plays a role in the level of correlation seen with viral neutralization assays, it is important to note that differences in viral neutralization assay formats also impact the ability to directly compare these results to one other. Furthermore, the variability in the immune response of patients recovering from COVID-19 disease 12 and the extent to which patients mount maladaptive innate immune responses leading to high plasma cytokine levels 13 may help explain the variability in serologic assay versus neutralization assay correlation seen with differing patient cohorts. Rychert and colleagues demonstrated the utility of IgG serologic assays in predicting a neutralizing antibody response. It is important to remember that a neutralizing antibody test assesses the ability of antibodies to prevent viral replication in vitro-an environment lacking the complex physiologic processes that occur in the human body.

Specifically, the inability of in-vitro neutralizing antibody tests to account for cellular immunity may underestimate the level of protection a patient may have from re-infection. 14 Additionally,

we have yet to study how neutralizing antibodies are able to penetrate specific tissue where SARS-CoV-2 thrives and how comorbidities such as atherosclerosis and immunodeficiency play a role. Assessment of the exact minimum levels of neutralizing antibody required to elicit a protective immune response is needed. The Vyriad assay uses a 1:100 dilution to determine Damluji--7 antibody presence, however, the FDA investigational drug (IND) use requirements indicate that donor convalescent plasma should have a neutralizing antibody titer of at least 1:160. 2 Rychert's work provides reassurance that high throughput, readily accessible serologic binding assays do reflect the presence of neutralizing antibodies, but a cautionary note that titers of IgG, irrespective of epitope may not reflect the extent of conferred immunity. This will further challenge the optimal implementation of therapies such as convalescent plasma and speaks to the complexity of acquired immunity to SARS-CoV-2. 

Navigating COVID-19 Testing, Special Considerations for the Cardiovascular Clinician

The Role of Antibody Testing for SARS-CoV-2: Is There One?

C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study

Evaluation of Three SARS CoV-2 IgG

Antibody Assays and Correlation with Neutralizing Antibodies

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Cellular immune responses to covid-19